<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5181">
  <stage>Registered</stage>
  <submitdate>2/12/2014</submitdate>
  <approvaldate>2/12/2014</approvaldate>
  <nctid>NCT02308020</nctid>
  <trial_identification>
    <studytitle>A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain</studytitle>
    <scientifictitle>A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>I3Y-MC-JPBO</secondaryid>
    <secondaryid>15450</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <healthcondition>Non-small Cell Lung Cancer</healthcondition>
    <healthcondition>Melanoma</healthcondition>
    <healthcondition>Brain Metastases</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Brain</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Abemaciclib

Experimental: Part A: HER2+ Breast Cancer - Participants with HR+, HER2+ breast cancer.
200 milligrams (mg) abemaciclib given orally once every 12 hours on days 1-21 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

Experimental: Part B: HER2- Breast Cancer - Participants with HR+, HER2- breast cancer.
200 mg abemaciclib given orally once every 12 hours on days 1-21 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

Experimental: Part C: Surgical Resection - Participants with HR+ breast cancer, NSCLC, or melanoma with intracranial lesions for which surgical resection is clinically indicated.
200 mg abemaciclib given orally once every 12 hours for 5-14 days prior to surgical resection. Dosing may resume following wound healing on a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

Experimental: Part D: NSCLC - Participants with NSCLC.
200 milligrams mg (150 mg for participants receiving concurrent gemcitabine or pemetrexed) abemaciclib given orally once every 12 hours on days 1-21 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

Experimental: Part E: Melanoma - Participants with melanoma.
200 milligrams mg abemaciclib given orally once every 12 hours on days 1-21 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

Experimental: Part F: HR+ Breast Cancer, NSCLC, or Melanoma - Participants with HR+ breast cancer, NSCLC, or melanoma and leptomeningeal metastases.
200 milligrams mg abemaciclib given orally once every 12 hours on days 1-21 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.


Treatment: drugs: Abemaciclib
Administered orally

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR)</outcome>
      <timepoint>Baseline to Objective Disease Progression (Approximately 6 Months)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with CR, PR, Stable Disease (SD), Progressive Disease (PD), or Not Evaluable (NE): Best Overall Intracranial Response (BOIR)</outcome>
      <timepoint>Baseline to Earliest Objective Progression or Start of New Anticancer Therapy (Approximately 6 Months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of CR and PR: Duration of Intracranial Response (DOIR)</outcome>
      <timepoint>Date of Complete Response or Partial Response to Date of Objective Disease Progression or Death from Any Cause (Approximately 6 Months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Participants with BOIR of CR, PR, or SD: Intracranial Disease Control Rate (IDCR)</outcome>
      <timepoint>Baseline to Disease Progression or Start of New Anticancer Therapy (Approximately 6 Months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Participants with BOIR of CR, PR, or SD with Duration of SD for at Least 6 Months: Intracranial Clinical Benefit Rate (ICBR)</outcome>
      <timepoint>Baseline to Disease Progression or Start of New Anticancer Therapy (Approximately 6 Months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival</outcome>
      <timepoint>Baseline to Death from Any Cause (Approximately 18 Months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with a Best Response of CR or PR: Objective Response Rate (ORR)</outcome>
      <timepoint>Baseline to Disease Progression (Approximately 6 Months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Participants with a Best Overall Response of CR, PR, or SD: Disease Control Rate (DCR)</outcome>
      <timepoint>Baseline to Disease Progression or Start of New Anticancer Therapy (Approximately 6 Months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival</outcome>
      <timepoint>Baseline to Objective Disease Progression or Death from Any Cause (Approximately 6 Months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline to End of Study in Neurologic Symptoms on the MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) Scale</outcome>
      <timepoint>Baseline, End of Study (Approximately 6 Months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics (PK): Minimum Concentration (Cmin) of Abemaciclib and its Metabolites</outcome>
      <timepoint>Cycle 1 through Cycle 4 (Approximately 3 Months)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Have brain metastases secondary to hormone receptor positive breast cancer, NSCLC, or
             melanoma.

          -  Have either human epidermal growth factor receptor 2 positive (HER2+) (Study Part A)
             or HER2- (Study Part B) breast cancer.

          -  Participants in Study Part C must have HR+ breast cancer, NSCLC, or melanoma with
             brain lesions clinically indicated for surgical resection as well as consent to
             provide tissue for drug concentration determination after 5 to 14 days of study drug
             dosing.

          -  Participants in Part D must have NSCLC of any subtype.

          -  Participants in Part E must have melanoma of any subtype.

          -  Participants in Part F must have HR+ breast cancer, NSCLC, or melanoma with
             leptomeningeal metastases.

          -  For Parts A, B, D, and E: Must have at least 1 measurable brain lesion =10 millimeters
             (mm) in the longest diameter (LD).

          -  For Part C (surgical): Have metastatic brain lesion(s) for which surgical resection is
             clinically indicated.

          -  Have completed local therapy (surgical resection, WBRT, or SRS) =14 days prior to
             initiating abemaciclib and recovered from all acute effects.

          -  If receiving concomitant corticosteroids, must be on a stable or decreasing dose for
             at least 7 days prior to the baseline Gd-MRI.

          -  Have a Karnofsky performance status of =70.

          -  Have a life expectancy =12 weeks.

          -  For HR+ breast cancer participants in part A, B, C, and F: If currently receiving
             endocrine therapy, a participant may continue to receive the same endocrine therapy
             provided that extracranial disease is stable for at least 3 months and central nervous
             system (CNS) disease progression has occurred while on this endocrine therapy. If
             these conditions are not met, participants must discontinue endocrine therapy prior to
             initiation of abemaciclib.

          -  For HER2+ breast cancer participants in parts A, C, and F: participants may receive
             concurrent treatment (ongoing or initiated simultaneously with abemaciclib) with IV
             trastuzumab.

          -  For NSCLC participants in parts C, D, and F: if currently receiving gemcitabine or
             pemetrexed (single-agent or in combination with another therapy), a participant may
             continue to receive 1 of these 2 therapies provided that extracranial disease is
             stable for at least 6 weeks and CNS disease progression has occurred while on this
             therapy.

          -  Have adequate organ function.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Require immediate local therapy, including but not limited to WBRT, SRS, or surgical
             resection, for treatment of brain metastases.

          -  Are taking concurrent enzyme-inducing antiepileptic drugs (EIAED).

          -  Have evidence of significant (ie, symptomatic) intracranial hemorrhage.

          -  For Parts A, B, C, D, E: Have evidence of leptomeningeal metastases. Note: discrete
             dural metastases are permitted.

          -  Have experienced &gt;2 seizures within 4 weeks prior to study entry.

          -  For Parts A, B, D, E, and F: Have previously received treatment with any cyclin
             dependent kinase 6 (CDK6) inhibitor. For Part C participants may have received prior
             palbociclib or ribociclib, but not abemaciclib treatment.

          -  Have known contraindication to Gd-MRI.

          -  Have a preexisting chronic condition resulting in persistent diarrhea.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>247</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Nedlands</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Newcastle</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Southport</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Woolloongabba</hospital>
    <postcode>6009 - Nedlands</postcode>
    <postcode>2298 - Newcastle</postcode>
    <postcode>4215 - Southport</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Charleroi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ottawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon Cedex 08</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 05</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint-Brieuc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv Jaffa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Cona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Grafton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main purpose of this study is to evaluate the safety and effectiveness of the study drug
      known as abemaciclib in participants with hormone receptor positive breast cancer, non-small
      cell lung cancer (NSCLC), or melanoma that has spread to the brain.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02308020</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Call 1-877-CTLILLY (1-877-285-459) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</name>
      <address />
      <phone>1-317-615-4559</phone>
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>